Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02050854 · ClinicalTrials.gov registry record
Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia
A clinical trial, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- 47
- Enrollment target
NCT02050854 is a clinical trial that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 47 participants.
The verdict
NCT02050854 has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- 47 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the pharmacokinetics of aripiprazole in subjects with Bipolar 1 Disorder or Schizophrenia who have a history of suboptimal aderence and are currently on treatment with oral aripiprazole.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2013-12 |
| Est. Completion | 2014-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02050854
The ClinicalTrials.gov registry entry for NCT02050854 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02050854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02050854 about?
NCT02050854 is a clinical study titled "Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia". The purpose of this study is to evaluate the pharmacokinetics of aripiprazole in subjects with Bipolar 1 Disorder or Schizophrenia who have a history of suboptimal aderence and are currently on treatment with oral aripiprazole.
What is the current status of trial NCT02050854?
This trial is currently completed. The enrollment target is 47 participants. The study started on 2013-12. Estimated completion is 2014-01.
Who is sponsoring clinical trial NCT02050854?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.